Kyntra Bio (LTS:0IL8) Interest Expense: $-8.93 Mil (TTM As of Mar. 2026)


LTS:0IL8 Kyntra Bio Inc LTS:0IL8
50 GF Score
Price $7.45
GF Value $5.70
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Kyntra Bio Interest Expense?

Kyntra Bio LTS:0IL8 -1.94% 50 Interest Expense is $-8.93 Mil as of Mar. 2026. GuruFocus rates LTS:0IL8 with a GF Score™ of 50/100 and a GF Value™ of $5.70 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Kyntra Bio's interest expense for the three months ended in Mar. 2026 was $ -2.43 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.93 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Kyntra Bio's Operating Income for the three months ended in Mar. 2026 was $ -13.80 Mil. Kyntra Bio's Interest Expense for the three months ended in Mar. 2026 was $ -2.43 Mil. Kyntra Bio did not have earnings to cover the interest expense. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kyntra Bio  (LTS:0IL8) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Kyntra Bio's Interest Expense for the three months ended in Mar. 2026 was $-2.43 Mil. Its Operating Income for the three months ended in Mar. 2026 was $-13.80 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was $0.00 Mil.

Kyntra Bio's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Kyntra Bio did not have earnings to cover the interest expense.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Kyntra Bio Interest Expense Historical Data

* Premium members only.

The historical data trend for Kyntra Bio's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyntra Bio Interest Expense Chart

Kyntra Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.15 -1.44 -8.10 -8.25 -8.76

Kyntra Bio Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.26 -2.01 -2.08 -2.41 -2.43
LTS:0IL8
50GF Score
Kyntra Bio Inc LTS:0IL8
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyntra Bio Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-8.93 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of $-8.93 Mil mean?
Kyntra Bio (LTS:0IL8) has a Interest Expense of $-8.93 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kyntra Bio and its competitors.
Is Kyntra Bio's Interest Expense too high?
Kyntra Bio's current Interest Expense is $-8.93 Mil. Overall, Kyntra Bio has a GF Score™ of 50/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Kyntra Bio's Interest Expense compare to TVGN and PSTV?
Kyntra Bio's Interest Expense of $-8.93 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Kyntra Bio and its competitors. Kyntra Bio's current Interest Expense is $-8.93 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyntra Bio stock overvalued right now?
Based on GuruFocus' analysis, Kyntra Bio (LTS:0IL8) is currently considered Significantly Overvalued. The stock's GF Value™ is $5.70, compared to a current price of $7.45 — trading 30.8% above its estimated fair value. The current Interest Expense is $-8.93 Mil. Kyntra Bio's overall GF Score™ is 50/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Kyntra Bio (LTS:0IL8), the current Interest Expense is $-8.93 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Kyntra Bio (LTS:0IL8) Overvalued in 2026?

Based on GuruFocus' analysis, Kyntra Bio stock appears to be overvalued. The current stock price of $7.45 is trading 30.8% above its estimated GF Value™ of $5.70. GuruFocus considers Kyntra Bio to be Significantly Overvalued.

Key valuation signals for LTS:0IL8:

  • Interest Expense: $-8.93 Mil
  • GF Value™: $5.70 vs. price of $7.45 (30.8% above fair value)
  • GF Score™: 50/100 with 8 warning signs

No single metric tells the full story. See the LTS:0IL8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Kyntra Bio Business Description

Address 350 Bay Street, Suite 100, No. 6009, San Francisco, CA, USA, 94133
Kyntra Bio Inc is a biopharmaceutical company focused on the development of novel therapies in oncology and rare disease. The company's research programs target cancer and rare disease indications, including anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) and metastatic castration-resistant prostate cancer (mCRPC). Itd pipeline drug candidates include Roxadustat and FG-3246.
50GF Score

Get the complete analysis for LTS:0IL8

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.45
Price
$5.70
GF Value